
RAFT-AF #ACC21



Trial Description: Patients with AF and HF were randomized in a 1:1 fashion to either catheter ablation or drug therapy. Patients were followed for a median duration of 37.4 months. Trial terminated early due to futility concerns.



RESULTS

- Primary endpoint, death and HF events for rhythm vs. rate control: 23.4% vs. 32.5% (HR 0.71, 95% CI 0.49-1.03, p = 0.066)
 - Among patients with EF ≤45% at baseline: HR 0.63, 95% CI 0.39-1.0 (p = 0.059)
- Minnesota Living With Heart Failure Questionnaire: change from baseline to 24 months: -17.4 vs. -14.8 (p = 0.0036)
- 6-minute walk distance to 24 months: 44.9 vs. 27.5 m (p = 0.025)
- Change in LVEF from baseline at 24 months: 10.1 vs. 3.8% (p = 0.017)

CONCLUSIONS

- A rhythm control strategy (via AF ablation) is not superior to a rate control strategy for CV outcomes at 5 years among patients with AF and HF. This in the context of early termination of the trial
- Significant improvements were noted in functional and serum biomarkers, including NT-proBNP. AF was significantly reduced with rhythm-control strategy

Presented by Dr. Anthony Tang at ACC.21